Gapping up
In reaction to strong earnings/guidance: OCLS +9.8%, KFY +3.8%, RH +1.2%
M&A news: TMUS +3.6% (WSJ reporting Dish (DISH) is looking to raise $10-15 bln to fund a bid to acquire the company), DISH +1.6% (WSJ reporting Dish (DISH) is looking to raise $10-15 bln to fund a bid to acquire the company)
Other news: OSUR +8.8% (awarded a contract for up to $10.4 mln in total funding from the U.S. Dept. of Health and Human Services), SNSS +7.5% (announces additional results of its VALOR trial; improved survival in patients =60), CALA +4.7% ( announces additional data from a study of its glutaminase inhibitor CB-839 ), CDTI +4.6% ( discloses entry into a North American Purchase and Sale Agreement with Honda North America, whereby Honda agreed to purchase goods and related services from the Company), BOBE +3.4% ( Board of Directors has authorized the co to pursue a strategic transaction, for a portion of its restaurant properties ), AGIO +2.8% (announces new data from its ongoing Phase 1 study evaluating single agent AG-221), TWTR +2.6% ( announces that Dick Costolo has decided to step down as CEO effective July 1, 2015, Jack Dorsey named Interim CEO; Co reaffirms Q2 guidance ), CTIC +1.9% (CTI BioPharma and Baxter (BAX) report significant improvements in symptom score with Pacritinib, across all measured symptoms, compared to best available therapy), URI+1.4% (Jana Partner Nik Mittal has indicated Jana will take 6% stake in URI, according to Reuters), PEIX +0.8% (co and Aventine Renewable Energy Holdings (AVRW) stockholders have approved the proposed merger of the companies; completion expected on July 1, 2015)
Analyst comments: TNXP +3.1% (initiated with an Outperform at Oppenheimer; $18 tgt), URBN +2.1% (upgraded to Buy at BB&T Capital Mkts), HCP +1.8% (upgraded to Neutral from Underperform at Mizuho), CTXS +1.4% (upgraded to Buy from Neutral at BofA/Merrill; upgraded to Neutral from Underweight at Piper Jaffray), MNST +1.4% (upgraded to at ), DRI +0.9% (upgraded to Outperform from Neutral at Credit Suisse), TS +0.8% (upgraded to Buy from Neutral at UBS
)
In reaction to strong earnings/guidance: OCLS +9.8%, KFY +3.8%, RH +1.2%
M&A news: TMUS +3.6% (WSJ reporting Dish (DISH) is looking to raise $10-15 bln to fund a bid to acquire the company), DISH +1.6% (WSJ reporting Dish (DISH) is looking to raise $10-15 bln to fund a bid to acquire the company)
Other news: OSUR +8.8% (awarded a contract for up to $10.4 mln in total funding from the U.S. Dept. of Health and Human Services), SNSS +7.5% (announces additional results of its VALOR trial; improved survival in patients =60), CALA +4.7% ( announces additional data from a study of its glutaminase inhibitor CB-839 ), CDTI +4.6% ( discloses entry into a North American Purchase and Sale Agreement with Honda North America, whereby Honda agreed to purchase goods and related services from the Company), BOBE +3.4% ( Board of Directors has authorized the co to pursue a strategic transaction, for a portion of its restaurant properties ), AGIO +2.8% (announces new data from its ongoing Phase 1 study evaluating single agent AG-221), TWTR +2.6% ( announces that Dick Costolo has decided to step down as CEO effective July 1, 2015, Jack Dorsey named Interim CEO; Co reaffirms Q2 guidance ), CTIC +1.9% (CTI BioPharma and Baxter (BAX) report significant improvements in symptom score with Pacritinib, across all measured symptoms, compared to best available therapy), URI+1.4% (Jana Partner Nik Mittal has indicated Jana will take 6% stake in URI, according to Reuters), PEIX +0.8% (co and Aventine Renewable Energy Holdings (AVRW) stockholders have approved the proposed merger of the companies; completion expected on July 1, 2015)
Analyst comments: TNXP +3.1% (initiated with an Outperform at Oppenheimer; $18 tgt), URBN +2.1% (upgraded to Buy at BB&T Capital Mkts), HCP +1.8% (upgraded to Neutral from Underperform at Mizuho), CTXS +1.4% (upgraded to Buy from Neutral at BofA/Merrill; upgraded to Neutral from Underweight at Piper Jaffray), MNST +1.4% (upgraded to at ), DRI +0.9% (upgraded to Outperform from Neutral at Credit Suisse), TS +0.8% (upgraded to Buy from Neutral at UBS
)